{"groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"FG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"FG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"FG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"FG003","title":"Sora 400 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"275"},{"groupId":"FG001","numSubjects":"260"},{"groupId":"FG002","numSubjects":"122"},{"groupId":"FG003","numSubjects":"280"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"7"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"20"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"389"},{"groupId":"FG001","numSubjects":"393"},{"groupId":"FG002","numSubjects":"153"},{"groupId":"FG003","numSubjects":"389"}],"comment":"Randomized","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"386"},{"groupId":"FG001","numSubjects":"389"},{"groupId":"FG002","numSubjects":"153"},{"groupId":"FG003","numSubjects":"374"}],"comment":"One participant in T300+D and one in T75+D arm didn't receive Treme and were analyzed under the Durva mono arm in the safety analysis set","type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"104"},{"groupId":"FG001","numSubjects":"125"},{"groupId":"FG002","numSubjects":"30"},{"groupId":"FG003","numSubjects":"82"}],"comment":"Completed final analysis and ongoing in long-term follow-up","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"285"},{"groupId":"FG001","numSubjects":"268"},{"groupId":"FG002","numSubjects":"123"},{"groupId":"FG003","numSubjects":"307"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Of 1,950 participants screened in the study, 1,324 were randomized across 4 arms, out of which 1,302 participants received treatment.","recruitmentDetails":"The study includes 1324 participants. Participants were screened in 16 countries from Oct2017 to Jun2019. Recruitment in T75+D arm was closed during the study. Results are reported at data cut-off (DCO)."}